Literature DB >> 9844042

Inflammatory cell infiltrate in a responding metastatic nodule after vaccine-based immunotherapy.

T F Logan1, B Banner, U Rao, M S Ernstoff, N Wolmark, T L Whiteside, L Miketic, J M Kirkwood.   

Abstract

A patient with von Hippel Lindau disease, bilateral symmetric renal cell carcinoma and pulmonary metastases treated with immunotherapy is the subject of this study. A left kidney and tumour mass were removed and the tumour cells used to make an autologous tumour/bacille Calmette-Guérin (BCG) vaccine as part of the treatment protocol. The patient's pulmonary nodules responded, but the remaining renal nodule subsequently grew. Samples of both tumours were obtained allowing for an internally controlled evaluation of the histological and immunohistologic differences between a responding and non-responding tumour nodule after therapy. The immunotherapy protocol is designed to promote a T cell response to autologous tumour. Cellular infiltrates were demonstrated in both responding and non-responding nodules compared with the pretreatment tumour specimen, but the responding nodule contained proportionately more T cells as well as markedly increased numbers of plasma cells and granulocytes. This suggested that several arms of the immune system may have been operative in the responding nodule.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9844042      PMCID: PMC1905123          DOI: 10.1046/j.1365-2249.1998.00731.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  33 in total

1.  Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients.

Authors:  D Berd; H C Maguire; P McCue; M J Mastrangelo
Journal:  J Clin Oncol       Date:  1990-11       Impact factor: 44.544

2.  von Hippel-Lindau disease.

Authors:  J M Connor
Journal:  Q J Med       Date:  1990-11

Review 3.  Natural killer cytotoxicity in the diagnosis of immune dysfunction: criteria for a reproducible assay.

Authors:  T L Whiteside; J Bryant; R Day; R B Herberman
Journal:  J Clin Lab Anal       Date:  1990       Impact factor: 2.352

4.  Lymphocytes generated by in vivo priming and in vitro sensitization demonstrate therapeutic efficacy against a murine tumor that lacks apparent immunogenicity.

Authors:  S Y Shu; T Chou; K Sakai
Journal:  J Immunol       Date:  1989-07-15       Impact factor: 5.422

5.  Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen.

Authors:  D R Parkinson; R I Fisher; A A Rayner; E Paietta; K A Margolin; G R Weiss; J W Mier; M Sznol; E R Gaynor; M H Bar
Journal:  J Clin Oncol       Date:  1990-10       Impact factor: 44.544

6.  Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans.

Authors:  J T Rubin; L J Elwood; S A Rosenberg; M T Lotze
Journal:  Cancer Res       Date:  1989-12-15       Impact factor: 12.701

7.  A phase IA trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma.

Authors:  M S Ernstoff; S Nair; R R Bahnson; L M Miketic; B Banner; W Gooding; R Day; T Whiteside; T Hakala; J M Kirkwood
Journal:  J Clin Oncol       Date:  1990-10       Impact factor: 44.544

8.  Clinical features and natural history of von Hippel-Lindau disease.

Authors:  E R Maher; J R Yates; R Harries; C Benjamin; R Harris; A T Moore; M A Ferguson-Smith
Journal:  Q J Med       Date:  1990-11

Review 9.  von Hippel-Lindau disease affecting 43 members of a single kindred.

Authors:  J M Lamiell; F G Salazar; Y E Hsia
Journal:  Medicine (Baltimore)       Date:  1989-01       Impact factor: 1.889

10.  Expression of intercellular adhesion molecule-1 (ICAM-1) on renal-cell cancer: possible significance in host immune responses.

Authors:  Y Tomita; T Nishiyama; H Watanabe; M Fujiwara; S Sato
Journal:  Int J Cancer       Date:  1990-12-15       Impact factor: 7.396

View more
  1 in total

1.  Clinical course and immune response of a renal cell carcinoma patient to adoptive transfer of autologous cytotoxic T lymphocytes.

Authors:  K Kawai; K Saijo; T Oikawa; Y Morishita; M Noguchi; T Ohno; H Akaza
Journal:  Clin Exp Immunol       Date:  2003-11       Impact factor: 4.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.